LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

Fresenius Medical Care AG & Co KGaA

Open

25.29 0.84

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

24.88

Max

25.31

Belangrijke statistieken

By Trading Economics

Inkomsten

83M

272M

Verkoop

-90M

4.8B

K/W

Sectorgemiddelde

19.769

35.733

Dividendrendement

3.06

Winstmarge

5.683

Werknemers

112,445

EBITDA

82M

822M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+22.12% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

3.06%

3.13%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

446M

15B

Vorige openingsprijs

24.45

Vorige sluitingsprijs

25.29

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

Fresenius Medical Care AG & Co KGaA Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 aug 2025, 08:51 UTC

Marktinformatie
Winsten

Fresenius Medical Care Has Work to Do to Reach Targets -- Market Talk

30 mei 2025, 12:58 UTC

Marktinformatie

Weaker Dollar to Weigh on European Luxury, Healthcare, Aerospace Sectors -- Market Talk

6 mei 2025, 07:06 UTC

Marktinformatie
Winsten

Fresenius Medical Care's Results Are Solid But U.S. Dialysis Treatment Growth Disappoints -- Market Talk

6 mei 2025, 06:42 UTC

Marktinformatie
Winsten

Fresenius Medical Care's Results Should Lead to Positive Market Reaction -- Market Talk

21 mrt 2025, 08:19 UTC

Marktinformatie

Fresenius Medical Care's Revenue Estimates Lowered by Jefferies on U.S. Volume Concerns -- Market Talk

25 feb 2025, 10:27 UTC

Marktinformatie
Winsten

Fresenius Medical Care's U.S. Volume Growth Is Unlikely to Reassure Investors -- Market Talk

Peer Vergelijking

Prijswijziging

Fresenius Medical Care AG & Co KGaA Prognose

Koersdoel

By TipRanks

22.12% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 30.25 USD  22.12%

Hoogste 34.5 USD

Laagste 27 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Fresenius Medical Care AG & Co KGaA - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

4 ratings

2

Buy

2

Hold

0

Sell

Technische score

By Trading Central

25.57 / 28.18Steun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Weak Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Fresenius Medical Care AG & Co KGaA

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
help-icon Live chat